Molly Henderson's Net Worth

$3.97 Million

Estimate Recalculated Oct 8, 2025 09:10PM EST

Who is Molly Henderson

Molly Henderson has an estimated net worth of $3.97 Million. This is based on reported shares across multiple companies, which include Phathom Pharmaceuticals, Inc., Lion Biotechnologies, Inc., UroGen Pharma Ltd., Advaxis, Inc., and VirtualScopics, Inc..

SEC CIK

Molly Henderson's CIK is 0001363812

Past Insider Trading and Trends

2022 was Molly Henderson's most active year for acquiring shares with 8 total transactions. Molly Henderson's most active month to acquire stocks was the month of December. 2023 was Molly Henderson's most active year for disposing of shares, totalling 7 transactions. Molly Henderson's most active month to dispose stocks was the month of October. 2021 saw Molly Henderson paying a total of $39,625.00 for 30,500 shares, this is the most they've acquired in one year. In 2023 Molly Henderson cashed out on 24,160 shares for a total of $218,142.44, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Phathom Pharmaceuticals, Inc.

CFO and CBO
Updated Jul 17, 2024
Form 4
-4.17%
-4.33K
$11.72
-$50.69K
Jul 17, 2024
101.36K
Sale
Jul 15
Form 4
7.87%
7.50K
May 31, 2024
104.67K
Grant
May 31
Form 4
-3.48%
-3.44K
$11.10
-$38.13K
Apr 10, 2024
97.17K
Sale
Apr 08
Form 4
108.27%
113.69K
$7.75
-$48.90K
Jan 22, 2024
220.61K
Grant
Jan 18 - Jan 19
Form 4
-2.02%
-2.13K
$7.24
-$15.40K
Nov 21, 2023
104.20K
Sale
Nov 20
Form 4
10.51%
10.01K
$8.88
-$110.87K
Nov 03, 2023
106.32K
Grant
Nov 01
Form 4/A
35.62%
25.00K
Jul 21, 2023
95.18K
Grant
Jul 14
Form 4
35.62%
25.00K
$1.00
$25.00K
Jul 17, 2023
96.31K
Grant
Jul 14
Form 4
-2.78%
-1.96K
$11.41
-$22.37K
Jun 05, 2023
68.84K
Sale
Jun 02
Form 4
-2.91%
-2.11K
$12.87
-$27.16K
May 23, 2023
70.80K
Sale
May 22
Form 4
-4.52%
-3.44K
$7.27
-$25.00K
Apr 07, 2023
72.91K
Sale
Apr 06
Form 4
-2.60%
-2.03K
$8.53
-$17.33K
Mar 03, 2023
76.35K
Sale
ScheduledMar 01
Form 4
195.35%
88.00K
Jan 20, 2023
133.39K
Grant
Jan 19
Form 4
-4.75%
-2.16K
$9.60
-$20.73K
Nov 23, 2022
43.68K
Sale
Nov 21
Form 4
19.74%
7.50K
Sep 02, 2022
45.84K
Grant
Sep 01
Form 4
46.15%
12.00K
May 20, 2022
38.00K
Grant
May 19
Form 4
30.00%
6.00K
May 16, 2022
26.00K
Purchase
May 13
Form 4
120.00K
Apr 06, 2022
120.00K
Grant
Apr 05
Form 3
Apr 06, 2022
Showing 19 results

Lion Biotechnologies, Inc.

CFO
Updated Jun 15, 2016
Form 4
200.00K
Jun 15, 2016
200.00K
Grant
Jun 01 - Jun 10
Form 4
100.00K
Mar 15, 2016
100.00K
Grant
Mar 11
Form 4
21.12K
Dec 30, 2015
21.12K
Grant
Dec 28
Form 4
200.00K
Jun 10, 2015
200.00K
Grant
Jun 08
Form 3
Jun 10, 2015
Showing 5 results

UroGen Pharma Ltd.

Chief Financial Officer
Updated Feb 02, 2022
Form 4
537.67%
37.17K
$7.58
-$2.51K
Feb 02, 2022
44.08K
Sell-Options
Jan 31
Form 4
-14.78%
-2.59K
$12.03
-$31.12K
Dec 02, 2021
14.91K
Sale
Nov 30
Form 4
15.00K
Jun 08, 2021
15.00K
Grant
Jun 05
Form 4
2.50K
$15.85
$39.63K
May 18, 2021
2.50K
Purchase
May 17
Form 4
8.00K
Feb 02, 2021
8.00K
Grant
Jan 31
Form 4
75.00K
Oct 05, 2020
75.00K
Grant
Oct 01
Form 3
Oct 05, 2020
Showing 7 results

Advaxis, Inc.

Executive Vice President & CFO
Updated May 05, 2020
Form 4
50.00K
May 05, 2020
50.00K
Grant
May 04
Form 4
25.00K
Oct 25, 2019
25.00K
Grant
Oct 24
Form 4
75.01%
2.50K
$3.68
$9.20K
Apr 11, 2019
5.83K
Grant
Apr 11
Form 4
3.00K
$3.86
$11.58K
Apr 10, 2019
3.00K
Grant
Apr 09
Form 4
125.00K
Nov 07, 2018
125.00K
Grant
Nov 05
Form 4
5.00K
$1.89
$9.45K
Jun 13, 2018
5.00K
Grant
Jun 12
Form 4
250.00K
Jun 08, 2018
250.00K
Grant
Jun 06
Form 3
Jun 08, 2018
Showing 8 results

VirtualScopics, Inc.

Chief Executive Officer
Updated May 30, 2006
Form 3
May 30, 2006
Form 3
May 30, 2006
Showing 2 results